ERX1000 vs metreleptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Leptin · full Obesity pipeline
ERX1000
Developed by ERX Pharmaceuticals
NCT04890873 · Phase 1 · completed
Participants were randomized to ERX1000 or a matching placebo with blinding of both participants and investigators, but the primary endpoints reported are safety measures (adverse events, laboratory, ECG, vital-sign, and exam abnormalities) rather than weight or metabolic efficacy, and no results have been posted. Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: May 2027 · NCT07570758 (registry estimate)
No aligned efficacy figure on record for this race.
metreleptin · Myalept
Marketed by Chiesi Farmaceutici
NCT01155180 · Phase 2 · completed
The trial was randomized, double-blind, and placebo-controlled, but it included only 24 participants (18 leptin and 6 placebo), making it small for a controlled comparison. Its clinical primary endpoint was not accompanied by a reported p-value or confidence interval, so whether the treatment comparison was statistically significant is unclear.
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ERX1000 | metreleptin |
|---|---|---|
| Body weight, % change | —Not reported | -6.4% vs -2.0%−4.4 vs placeboNCT0067338725 other results
|
| Weight loss of 5% or more | —Not reported | —Not reported |
| Weight loss of 10% or more | —Not reported | —Not reported |
| Waist circumference, change (cm) | —Not reported | -4.7 vs -2.5−2.2 vs placeboNCT0067338731 other results
|
Body weight, % change
- ERX1000
- —Not reported
- metreleptin
- -6.4% vs -2.0%−4.4 vs placeboNCT00673387
25 other results
- -7.0% vs -2.0% NCT00673387
- -7.0% vs -2.0% NCT00673387
- -6.8% vs -2.0% NCT00673387
- -6.6% vs -2.0% NCT00673387
- -5.8% vs -2.0% NCT00673387
- -3.6% vs -3.9% NCT00392925
- -8.2% vs -3.9% NCT00392925
- -8.2% vs -8.4% NCT00392925
- -12.7% vs -8.4% NCT00392925
- -3.4% vs -3.9% NCT00392925
- -7.6% vs -3.9% NCT00392925
- -8.0% vs -8.4% NCT00392925
- -12.1% vs -8.4% NCT00392925
- -3.2% vs -3.4% NCT00392925
- -6.1% vs -3.4% NCT00392925
- -7.8% vs -8.0% NCT00392925
- -10.8% vs -8.0% NCT00392925
- -2.1% vs -2.7% NCT00392925
- -4.8% vs -2.7% NCT00392925
- -6.8% vs -7.3% NCT00392925
- -9.5% vs -7.3% NCT00392925
- -0.7% vs -1.6% NCT00392925
- -2.4% vs -1.6% NCT00392925
- -5.5% vs -6.2% NCT00392925
- -7.2% vs -6.2% NCT00392925
Weight loss of 5% or more
- ERX1000
- —Not reported
- metreleptin
- —Not reported
Weight loss of 10% or more
- ERX1000
- —Not reported
- metreleptin
- —Not reported
Waist circumference, change (cm)
- ERX1000
- —Not reported
- metreleptin
- -4.7 vs -2.5−2.2 vs placeboNCT00673387
31 other results
- -5.5 vs -2.5 NCT00673387
- -6.5 vs -2.5 NCT00673387
- -3.3 vs -3.0 NCT00673387
- -4.6 vs -3.0 NCT00673387
- -5.2 vs -3.0 NCT00673387
- -5.5 vs -2.5 NCT00673387
- -5.8 vs -2.5 NCT00673387
- -4.9 vs -3.0 NCT00673387
- -4.3 vs -3.0 NCT00673387
- -3.9 vs -2.5 NCT00673387
- -3.4 vs -3.0 NCT00673387
- -8.0 vs -9.2 NCT00392925
- -11.6 vs -9.2 NCT00392925
- -3.6 vs -4.9 NCT00392925
- -7.3 vs -4.9 NCT00392925
- -6.8 vs -9 NCT00392925
- -10.7 vs -9 NCT00392925
- -2.4 vs -4.8 NCT00392925
- -6.3 vs -4.8 NCT00392925
- -7.1 vs -8.5 NCT00392925
- -9.9 vs -8.5 NCT00392925
- -2.6 vs -4.2 NCT00392925
- -5.5 vs -4.2 NCT00392925
- -5.7 vs -7.8 NCT00392925
- -8.8 vs -7.8 NCT00392925
- -1.3 vs -3.5 NCT00392925
- -4.4 vs -3.5 NCT00392925
- -5.5 vs -6.8 NCT00392925
- -7.3 vs -6.8 NCT00392925
- -1.1 vs -2.5 NCT00392925
- -3.0 vs -2.5 NCT00392925
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ERX1000: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ERX1000: 0 of 4 rows · metreleptin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | metreleptin |
|---|---|
| Dropout rate | —Pramlintide 360 mcg + Metreleptin 1.25 mga NCT00819234 · Phase 2 · registry result, not featured evidence · combination show 18 more results42.9%Pramlintide 360 mcg + Metreleptin 1.25 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 22.2%Pramlintide 360 mcg + Metreleptin 2.5 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 16.2%Pramlintide 360 mcg + Metreleptin 2.5 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination —Pramlintide 360 mcg + Metreleptin 2.5 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 21.4%Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 18.9%Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 31%Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination —Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 43.6%360 mcg + 1.25 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 38.5%360 mcg + 2.5 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 46.7%360 mcg + 5.0 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 34.7%180 mcg + 2.5 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 38.5%180 mcg + 5.0 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 43.1%5.0 mg NCT00673387 · Phase 2 · registry result, not featured evidence —Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence —Placebo + Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence —Pramlintide + Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence · combination —Pramlintide Acetate + Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —Pramlintide 360 mcg + Metreleptin 1.25 mga NCT00819234 · Phase 2 · registry result, not featured evidence · combination show 18 more results0%Pramlintide 360 mcg + Metreleptin 1.25 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 2.8%Pramlintide 360 mcg + Metreleptin 2.5 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 0%Pramlintide 360 mcg + Metreleptin 2.5 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination —Pramlintide 360 mcg + Metreleptin 2.5 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 0%Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 0%Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 0%Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination —Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 2.6%360 mcg + 1.25 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 6.4%360 mcg + 2.5 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 6.7%360 mcg + 5.0 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 2.7%180 mcg + 2.5 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 7.7%180 mcg + 5.0 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 6.9%5.0 mg NCT00673387 · Phase 2 · registry result, not featured evidence —Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence —Placebo + Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence —Pramlintide + Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence · combination —Pramlintide Acetate + Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 0%Pramlintide 360 mcg + Metreleptin 1.25 mga NCT00819234 · Phase 2 · registry result, not featured evidence · combination show 18 more results0%Pramlintide 360 mcg + Metreleptin 1.25 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 0%Pramlintide 360 mcg + Metreleptin 2.5 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 2.7%Pramlintide 360 mcg + Metreleptin 2.5 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 0%Pramlintide 360 mcg + Metreleptin 2.5 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 0%Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 2.7%Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 6.9%Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 0%Pramlintide 360 mcg + Metreleptin 5.0 mg NCT00819234 · Phase 2 · registry result, not featured evidence · combination 0%360 mcg + 1.25 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 0%360 mcg + 2.5 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 2.7%360 mcg + 5.0 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 2.7%180 mcg + 2.5 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 0%180 mcg + 5.0 mg NCT00673387 · Phase 2 · registry result, not featured evidence · combination 0%5.0 mg NCT00673387 · Phase 2 · registry result, not featured evidence —Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence 3.7%Placebo + Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence 3.6%Pramlintide + Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence · combination —Pramlintide Acetate + Metreleptin NCT00392925 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | Pramlintide 360 mcg + Metreleptin 1.25 mga upper respiratory tract infection 23.1% (placebo 9.7%) diarrhea 15.4% (placebo 3.2%) injection site hemorrhage 15.4% (placebo 3.2%) NCT00819234 · Phase 2 · registry result, not featured evidence · combination show 16 more resultsPramlintide 360 mcg + Metreleptin 1.25 mg nausea 8.6% (placebo 3.2%) upper respiratory tract infection 8.6% (placebo 9.7%) muscle spasms 5.7% (placebo 0%) NCT00819234 · Phase 2 · registry result, not featured evidence · combination Pramlintide 360 mcg + Metreleptin 2.5 mg sinusitis 19.4% (placebo 0%) upper respiratory tract infection 13.9% (placebo 9.7%) urinary tract infection 8.3% (placebo 0%) NCT00819234 · Phase 2 · registry result, not featured evidence · combination Pramlintide 360 mcg + Metreleptin 2.5 mg nausea 18.9% (placebo 3.2%) sinusitis 16.2% (placebo 0%) upper respiratory tract infection 10.8% (placebo 9.7%) NCT00819234 · Phase 2 · registry result, not featured evidence · combination Pramlintide 360 mcg + Metreleptin 2.5 mg injection site pruritus 21.4% (placebo 0%) injection site urticaria 21.4% (placebo 0%) bronchitis 14.3% (placebo 0%) NCT00819234 · Phase 2 · registry result, not featured evidence · combination Pramlintide 360 mcg + Metreleptin 5.0 mg upper respiratory tract infection 25% (placebo 9.7%) nausea 17.9% (placebo 3.2%) influenza 10.7% (placebo 3.2%) NCT00819234 · Phase 2 · registry result, not featured evidence · combination Pramlintide 360 mcg + Metreleptin 5.0 mg upper respiratory tract infection 58.3% (placebo 9.7%) nausea 21.6% (placebo 3.2%) injection site hemorrhage 10.8% (placebo 3.2%) NCT00819234 · Phase 2 · registry result, not featured evidence · combination Pramlintide 360 mcg + Metreleptin 5.0 mg nausea 37.9% (placebo 3.2%) nasopharyngitis 17.2% (placebo 12.9%) gastroenteritis 10.3% (placebo 3.2%) NCT00819234 · Phase 2 · registry result, not featured evidence · combination Pramlintide 360 mcg + Metreleptin 5.0 mg injection site erythema 30.8% (placebo 0%) gastroenteritis 15.4% (placebo 3.2%) headache 15.4% (placebo 0%) NCT00819234 · Phase 2 · registry result, not featured evidence · combination 360 mcg + 1.25 mg nausea 33.3% (placebo 5.3%) injection site bruising 14.1% (placebo 14.7%) injection site pruritus 14.1% (placebo 1.3%) NCT00673387 · Phase 2 · registry result, not featured evidence · combination 360 mcg + 2.5 mg nausea 37.2% (placebo 5.3%) injection site erythema 30.8% (placebo 1.3%) injection site pruritus 23.1% (placebo 1.3%) NCT00673387 · Phase 2 · registry result, not featured evidence · combination 360 mcg + 5.0 mg injection site pruritus 29.3% (placebo 1.3%) injection site erythema 28% (placebo 1.3%) nausea 25.3% (placebo 5.3%) NCT00673387 · Phase 2 · registry result, not featured evidence · combination 180 mcg + 2.5 mg nausea 36% (placebo 5.3%) injection site pruritus 25.3% (placebo 1.3%) injection site erythema 20% (placebo 1.3%) NCT00673387 · Phase 2 · registry result, not featured evidence · combination 180 mcg + 5.0 mg injection site pruritus 26.9% (placebo 1.3%) nausea 26.9% (placebo 5.3%) injection site erythema 21.8% (placebo 1.3%) NCT00673387 · Phase 2 · registry result, not featured evidence · combination 5.0 mg injection site erythema 20.8% (placebo 1.3%) injection site hemorrhage 18.1% (placebo 4%) injection site pruritus 18.1% (placebo 1.3%) NCT00673387 · Phase 2 · registry result, not featured evidence injection site pruritus 25.9% nausea 25.9% injection site erythema 18.5% NCT00392925 · Phase 2 · registry result, not featured evidence injection site bruising 19.6% injection site urticaria 16.1% injection site erythema 14.3% NCT00392925 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
metreleptin
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 23 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ERX1000's landscape · metreleptin's landscape